Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy

Regulation of ROS in myeloid-derived suppressor cells through targeting fatty-acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy

(2021) Adeleye Oluwatosin Adeshakin et al.   CELLULAR IMMUNOLOGY

Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer

(2021) Mohamed A Ghonim et al.   Journal for ImmunoTherapy of Cancer

Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion

(2021) Isak W. Tengesdal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IDO1 Signaling Through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFNγ/IL6 Balance to Promote Neovascularization

(2021) Souvik Dey et al.   Cancer Immunology Research

Immunosuppressive Myeloid Cells Induce Nitric Oxide–Dependent DNA Damage and p53 Pathway Activation in CD8+ T Cells

(2021) Adam N.R. Cartwright et al.   Cancer Immunology Research

Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy

(2021) Pascale Hubert et al.   Journal for ImmunoTherapy of Cancer

Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy

(2021) Nicholas C. DeVito et al.   Cell Reports

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

(2021) Thomas Powles et al.   LANCET ONCOLOGY

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

(2021) Arjun V Balar et al.   LANCET ONCOLOGY

Estrogen inhibits the growth of colon cancer in mice through reversing extracellular vesicle-mediated immunosuppressive tumor microenvironment

(2021) Lingling Jiang et al.   CANCER LETTERS

Myeloid-derived suppressor cells impede T cell functionality and promote Th17 differentiation in oral squamous cell carcinoma

(2020) Asif A. Dar et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer

(2020) Shipra Das et al.   CANCER RESEARCH

The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction

(2020) Benjamin T Himes et al.   NEURO-ONCOLOGY

Deciphering the Crosstalk Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma

(2020) Carole Siret et al.   Frontiers in Immunology

Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression

(2020) Zhiqi Xie et al.   OncoImmunology

Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model

(2020) Jing Wu et al.   BIOMEDICINE & PHARMACOTHERAPY

Myeloid‐derived suppressor cells promote epithelial ovarian cancer cell stemness by inducing the CSF2/p‐STAT3 signalling pathway

(2020) Xiaofeng Li et al.   FEBS Journal

A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy

(2020) Balamayoora Theivanthiran et al.   JOURNAL OF CLINICAL INVESTIGATION

Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells

(2020) Kenji Otsuka et al.   LUNG CANCER

Chromatin Regulator, CHD1, Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer

(2020) Di Zhao et al.   Cancer Discovery

Eicosanoids in Cancer: Prostaglandin E2 Receptor 4 in Cancer Therapeutics and Immunotherapy

(2020) Mc Millan Ching et al.   Frontiers in Pharmacology

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer

(2020) Tian Zhang et al.   CANCER

The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer

(2020) Naoko Komura et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Palmitoylated proteins on AML-derived extracellular vesicles promote myeloid-derived suppressor cell differentiation via TLR2/Akt/mTOR signaling

(2020) Sehmus Tohumeken et al.   CANCER RESEARCH

Polyamine Blocking Therapy Decreases Survival of Tumor-Infiltrating Immunosuppressive Myeloid Cells and Enhances the Anti-Tumor Efficacy of PD-1 Blockade

(2020) Susan K. Gilmour et al.   MOLECULAR CANCER THERAPEUTICS

ALKBH5 regulates anti–PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment

(2020) Na Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers

(2020) David S Hong et al.   Journal for ImmunoTherapy of Cancer

CD200 promotes immunosuppression in the pancreatic tumor microenvironment

(2020) Fouad Choueiry et al.   Journal for ImmunoTherapy of Cancer

Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer

(2020) Alessio Ugolini et al.   JCI Insight

Pharmacological activation of estrogen receptor beta overcomes tumor resistance to immune checkpoint blockade therapy

(2020) Shuang Huang et al.   iScience

NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma

(2020) Fei Lu et al.   CANCER LETTERS

Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer

(2020) Weiqiang Lu et al.   EMBO Molecular Medicine

Obesity diminishes response to PD-1-based immunotherapies in renal cancer

(2020) Shannon K Boi et al.   Journal for ImmunoTherapy of Cancer

IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma

(2019) Alex B. Blair et al.   JOURNAL OF CLINICAL INVESTIGATION

Dual blockade of CXCL12-CXCR4 and PD-1–PD-L1 pathways prolongs survival of ovarian tumor–bearing mice by prevention of immunosuppression in the tumor microenvironment

(2019) Yang Zeng et al.   FASEB JOURNAL

Aurora-A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in breast cancer

(2019) Tingting Yin et al.   CANCER RESEARCH

KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer

(2019) Wenting Liao et al.   CANCER CELL

MicroRNA-92 expression in CD133+ melanoma stem cells regulates immunosuppression in the tumor microenvironment via integrin-dependent activation of TGF-β

(2019) Chris Shidal et al.   CANCER RESEARCH

Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2

(2019) Julien Cherfils‐Vicini et al.   EMBO JOURNAL

Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment

(2019) Adela Wu et al.   JOURNAL OF NEURO-ONCOLOGY

Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation

(2019) Lisha Ai et al.   Molecular Cancer

Fatty acid transport protein 2 reprograms neutrophils in cancer

(2019) Filippo Veglia et al.   NATURE

Mouse CD8+NKT-like cells exert dual cytotoxicity against mouse tumor cells and myeloid-derived suppressor cells

(2019) Zhengyuan Li et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Melanoma extracellular vesicles generate immunosuppressive myeloid cells by PD-L1 upregulation via TLR4 signaling

(2019) Viktor Fleming et al.   CANCER RESEARCH

Granulocytic Myeloid‐Derived Suppressor Cells Promote the Stemness of Colorectal Cancer Cells through Exosomal S100A9

(2019) Yungang Wang et al.   Advanced Science

Supplementary granulocyte macrophage colony‐stimulating factor to chemotherapy and programmed death‐ligand 1 blockade decreases local recurrence after surgery in bladder cancer

(2019) Makito Miyake et al.   CANCER SCIENCE

TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti–PD-1 Therapy in Melanoma

(2019) Alisha Holtzhausen et al.   Cancer Immunology Research

SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy

(2019) Kuo Jiang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy

(2019) Liangrong Shi et al.   Nature Communications

Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models

(2019) Sarah Greene et al.   CLINICAL CANCER RESEARCH

CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas

(2019) Joseph A. Flores-Toro et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of anti-angiogenic therapy

(2018) Raimund Bauer et al.   CANCER RESEARCH

Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor–Mediated Natural Killer Cell Function

(2018) Andrew Stiff et al.   CLINICAL CANCER RESEARCH

Clinical relevance and suppressive capacity of human MDSC subsets

(2018) Stephan Lang et al.   CLINICAL CANCER RESEARCH

Arginase-1 is neither constitutively expressed in nor required for myeloid-derived suppressor cell-mediated inhibition of T-cell proliferation

(2018) Zhen Bian et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies

(2018) Shetal A. Patel et al.   IMMUNITY

IL-17 inhibits the accumulation of myeloid-derived suppressor cells in breast cancer via activating STAT3

(2018) Min Ma et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Dual TGF-β and PD-1 blockade synergistically enhances MAGE-A3-specific CD8+ T cell response in esophageal squamous cell carcinoma

(2018) Xinfeng Chen et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression

(2018) Viktor Fleming et al.   Frontiers in Immunology

Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab

(2018) Richard P. Tobin et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

(−)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer

(2018) HongYue Lin et al.   PHARMACEUTICAL RESEARCH

Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers

(2018) Shan Feng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression

(2018) Christopher Groth et al.   BRITISH JOURNAL OF CANCER

Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade

(2018) Hanna Grauers Wiktorin et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma

(2018) Veronica Huber et al.   JOURNAL OF CLINICAL INVESTIGATION

ΔNp63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer

(2018) Sushil Kumar et al.   JOURNAL OF CLINICAL INVESTIGATION

Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs

(2018) Brian J. Christmas et al.   Cancer Immunology Research

Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function

(2018) Paul E. Clavijo et al.   Cancer Immunology Research

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

(2018) Fatima Karzai et al.   Journal for ImmunoTherapy of Cancer

Specific inhibition of PI3Kδ/γ enhances the efficacy of anti-PD1 against osteosarcoma cancer

(2018) Xinge Shi et al.   Journal of Bone Oncology

A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells

(2017) Giada Mondanelli et al.   IMMUNITY

A proangiogenic signaling axis in myeloid cells promotes malignant progression of glioma

(2017) Yujie Huang et al.   JOURNAL OF CLINICAL INVESTIGATION

Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma

(2017) Sun Hye Kim et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Cancer stem cells revisited

(2017) Eduard Batlle et al.   NATURE MEDICINE

Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes

(2017) Jingjing Zhu et al.   Nature Communications

Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion

(2017) Kim De Veirman et al.   Cancer Immunology Research

EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity

(2017) Diana I. Albu et al.   OncoImmunology

Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression

(2016) Tobias Eggert et al.   CANCER CELL

Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling

(2016) D. Peng et al.   CANCER RESEARCH

Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma

(2016) Y. Mao et al.   CLINICAL CANCER RESEARCH

Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26

(2016) David Kung-Chun Chiu et al.   HEPATOLOGY

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

(2016) Axel Hoos   NATURE REVIEWS DRUG DISCOVERY

Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis

(2016) Z Deng et al.   ONCOGENE

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

(2016) Vincenzo Bronte et al.   Nature Communications

Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy

(2016) Rikke B. Holmgaard et al.   OncoImmunology

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors

(2016) Rikke B. Holmgaard et al.   EBioMedicine

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

(2015) Douglas Marvel et al.   JOURNAL OF CLINICAL INVESTIGATION

Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17–producing CD4+T cells

(2015) Myrna L. Ortiz et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cell-Mediated Control of T Cell Immunity

(2015) C. Cimen Bozkus et al.   JOURNAL OF IMMUNOLOGY

Extracellular vesicles as modulators of the cancer microenvironment

(2015) Jason Webber et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation

(2015) Marianna Papaspyridonos et al.   Nature Communications

Hypoxia and TGF-β1 lead to endostatin resistance by cooperatively increasing cancer stem cells in A549 transplantation tumors

(2015) Yuyi Wang et al.   Cell and Bioscience

ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells

(2015) David Gallego-Ortega et al.   PLOS BIOLOGY

HMGB1 Enhances Immune Suppression by Facilitating the Differentiation and Suppressive Activity of Myeloid-Derived Suppressor Cells

(2014) K. H. Parker et al.   CANCER RESEARCH

Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity

(2014) Y. Mao et al.   CLINICAL CANCER RESEARCH

The Wilms’ tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression

(2014) Kay-Dietrich Wagner et al.   Nature Communications

Tumor Microenvironmental Conversion of Natural Killer Cells into Myeloid-Derived Suppressor Cells

(2013) Y.-J. Park et al.   CANCER RESEARCH

Myeloid-Derived Suppressor Cells Enhance Stemness of Cancer Cells by Inducing MicroRNA101 and Suppressing the Corepressor CtBP2

(2013) Tracy X. Cui et al.   IMMUNITY

Extracellular vesicles: Exosomes, microvesicles, and friends

(2013) Graça Raposo et al.   JOURNAL OF CELL BIOLOGY

Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling

(2013) Nataša Obermajer et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Myeloid-Derived Suppressor Cells Confer Tumor-Suppressive Functions on Natural Killer Cells via Polyinosinic:Polycytidylic Acid Treatment in Mouse Tumor Models

(2013) Hiroaki Shime et al.   Journal of Innate Immunity

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

(2012) Mélanie Bruchard et al.   NATURE MEDICINE

Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL

(2011) P. Sinha et al.   BLOOD

Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells

(2011) B. Hoechst et al.   BLOOD

Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice

(2011) Tangying Lu et al.   JOURNAL OF CLINICAL INVESTIGATION

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells

(2011) Barbara Molon et al.   JOURNAL OF EXPERIMENTAL MEDICINE

IL-17 Promotes Tumor Development through the Induction of Tumor Promoting Microenvironments at Tumor Sites and Myeloid-Derived Suppressor Cells

(2010) Donggou He et al.   JOURNAL OF IMMUNOLOGY

Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function

(2010) Cheng-En Hu et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy

(2009) S. J. Priceman et al.   BLOOD

Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine

(2009) M. K. Srivastava et al.   CANCER RESEARCH

Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor

(2009) Bastian Hoechst et al.   HEPATOLOGY

Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells

(2008) N. Nausch et al.   BLOOD

Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice

(2008) Maciej Kujawski et al.   JOURNAL OF CLINICAL INVESTIGATION

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

(2008) Pingyan Cheng et al.   JOURNAL OF EXPERIMENTAL MEDICINE